Assembly Biosciences, Inc. $ASMB Shares Sold by Armistice Capital LLC

Key Points

• Armistice Capital LLC has significantly reduced its stake in Assembly Biosciences by 85.8%, now owning approximately 0.31%, valued at $228,000.
• Assembly Biosciences recently reported earnings of ($1.33) per share, exceeding analysts' expectations of ($1.73), with revenue of $9.63 million for the quarter.
• Analysts have rated Assembly Biosciences with a consensus of "Moderate Buy," and the company currently has an average price target of $38.67.

Armistice Capital LLC trimmed its holdings in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) by 85.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,858 shares of the biopharmaceutical company's stock after selling 144,216 shares during the period. Armistice Capital LLC owned approximately 0.31% of Assembly Biosciences worth $228,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of ASMB. JPMorgan Chase & Co. lifted its stake in Assembly Biosciences by 225.6% during the 4th quarter. JPMorgan Chase & Co. now owns 11,427 shares of the biopharmaceutical company's stock valued at $180,000 after acquiring an additional 7,918 shares during the period. Marshall Wace LLP lifted its stake in Assembly Biosciences by 16.5% during the 4th quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company's stock valued at $234,000 after acquiring an additional 2,098 shares during the period. Man Group plc acquired a new stake in Assembly Biosciences during the 4th quarter valued at approximately $309,000. Palumbo Wealth Management LLC lifted its stake in Assembly Biosciences by 57.4% during the 1st quarter. Palumbo Wealth Management LLC now owns 17,986 shares of the biopharmaceutical company's stock valued at $172,000 after acquiring an additional 6,559 shares during the period. Finally, American Century Companies Inc. acquired a new stake in Assembly Biosciences during the 1st quarter valued at approximately $113,000. 19.92% of the stock is currently owned by institutional investors and hedge funds.

Assembly Biosciences Trading Down 1.0%

ASMB traded down $0.23 on Wednesday, hitting $23.90. 130,276 shares of the company's stock were exchanged, compared to its average volume of 154,495. Assembly Biosciences, Inc. has a fifty-two week low of $7.75 and a fifty-two week high of $27.17. The firm has a 50-day moving average price of $21.07 and a 200-day moving average price of $15.42. The stock has a market cap of $183.31 million, a price-to-earnings ratio of -4.28 and a beta of 0.68.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.73) by $0.40. Assembly Biosciences had a negative net margin of 117.20% and a negative return on equity of 149.01%. The company had revenue of $9.63 million for the quarter, compared to analysts' expectations of $5.30 million. On average, equities analysts predict that Assembly Biosciences, Inc. will post -6.87 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ASMB shares. HC Wainwright started coverage on shares of Assembly Biosciences in a report on Monday, August 18th. They set a "buy" rating and a $50.00 target price for the company. Zacks Research raised shares of Assembly Biosciences to a "hold" rating in a report on Tuesday, August 19th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, Assembly Biosciences has a consensus rating of "Moderate Buy" and an average target price of $38.67.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.